Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 14 , ISSUE 1 ( January-June, 2024 ) > List of Articles

Original Article

Iron-deficiency Anemia Treatment with Ferric Carboxymaltose: A Real-world Quasi-experimental Study from Bangladesh

M Morsed Zaman Miah, Md Enayet Ali Pramanik, Abdur Rafi, Mira Akhter

Keywords : Efficacy and safety, Ferric carboxymaltose, Ferritin, Hemoglobin, Iron-deficiency anemia

Citation Information : Miah MM, Pramanik ME, Rafi A, Akhter M. Iron-deficiency Anemia Treatment with Ferric Carboxymaltose: A Real-world Quasi-experimental Study from Bangladesh. Euroasian J Hepatogastroenterol 2024; 14 (1):12-15.

DOI: 10.5005/jp-journals-10018-1422

License: CC BY-NC 4.0

Published Online: 12-06-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Gastrointestinal bleeding is the most common cause of iron deficiency in adult men and menstrual blood loss is the leading cause of iron insufficiency in women, anemia due to iron deficiency is mostly caused by blood loss. Ferric carboxymaltose (FCM) is a contemporary parenteral iron formulation that may be used therapeutically to treat anemia caused by an iron deficiency [iron-deficiency anemia (IDA)]. The main goal of the trial was to evaluate FCM's safety and efficacy in treating IDA. The Department of Hematology, Rajshahi Medical College Hospital, Rajshahi, Bangladesh participated in this quasi-experimental research, which comprised adult patients with IDA. Participants were given an intravenous (IV) infusion of 500 mg of FCM, diluted in 100 mL of 0.9% normal saline, throughout a 30-minute period after their participation. The second dosage of FCM was administered after a 7-day period of the first dose. The comparison of the outcomes [hemoglobin (Hb) level, serum ferritin level, and other hematological parameters] between the baseline and day 14 postintervention was done using a paired t-test. Compared to baseline, patients’ Hb levels rose considerably (p = 0.001) after FCM. Aside from serum ferritin level, additional hematological parameters that sharply increased were red blood cells (RBCs) count, mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width – coefficient of variation (RDW-CV), and iron indicators. The experiment recorded mild adverse effects such as fever, headaches, and gastrointestinal issues including vomiting, diarrhea, and constipation, but no significant adverse events. In summary, IDA may be effectively treated with FCM, a safe and secure IV medication that has no major negative effects.

PDF Share
  1. Safiri S, Kolahi A-A, Noori M, et al. Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: Results from the global burden of disease study 2019. J Hematol Oncol 2021;14(1):185. DOI: 10.1186/s13045-021-01202-2.
  2. Kassebaum NJ, GBD 2013 Anemia Collaborators, et al. The global burden of anemia. Hematol Oncol Clin North Am 2016;30(2):247–308. DOI: 10.1016/j.hoc.2015.11.002.
  3. Rahman MA, Rahman MS, Rahman MA, et al. Prevalence of and factors associated with anaemia in women of reproductive age in Bangladesh, Maldives and Nepal: Evidence from nationally-representative survey data. PloS One 2021;16(1):e0245335. DOI: 10.1371/journal.pone.0245335.
  4. Ning S, Zeller MP. Management of iron deficiency. Hematology Am Soc Hematol Educ Program 2019;2019(1):315–322. DPI: 10.1182/hematology.2019000034.
  5. Stoffel NU, von Siebenthal HK, Moretti D, et al. Oral iron supplementation in iron-deficient women: How much and how often? Mol Aspects Med 2020;75:100865. DOI: 10.1016/j.mam.2020. 100865.
  6. Stoltzfus RJ, Dreyfuss ML, WHO. Guidelines for the use of iron supplements to prevent and treat iron deficiency anemia. Washington, DC: ILSI Press, 1998.
  7. Ikuta K, Shimura A, Terauchi M, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous ferric carboxymaltose: A dose-escalation study in Japanese volunteers with iron-deficiency anemia. Int J Hematol 2018;107(5):519–527. DOI: 10.1007/s12185-018-2400-z.
  8. Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: Systematic review and meta-analysis. Mayo Clin Proc 2015;90(1):12–23. DOI: 10.1016/j.mayocp.2014.10.007.
  9. Moore RA, Gaskell H, Rose P, et al. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord 2011;11:4. DOI: 10.1186/1471-2326-11-4.
  10. Bregman DB, Goodnough LT. Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia. Ther Adv Hematol 2014;5(2):48–60. DOI: 10.1177/2040620714521127.
  11. Tsiolakidou G, Koutroubakis IE. Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World J Gastroenterol 2007;13(36):4798–4806. DOI: 10.3748/wjg.v13.i36.4798.
  12. Breymann C, Milman N, Mezzacasa A, et al. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: An international, open-label, randomized controlled trial (FER-ASAP). J Perinat Med 2017;45(4):443–453. DOI: 10.1515/jpm-2016-0050.
  13. Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: An individual patient data meta-analysis. Eur J Heart Fail 2018;20(1):125–133. DOI: 10.1002/ejhf.823.
  14. Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014;29(11):2075–2084. DOI: 10.1093/ndt/gfu201.
  15. Kim YW, Bae JM, Park YK, et al. Effect of intravenous ferric carboxymaltose on hemoglobin response among patients with acute isovolemic anemia following gastrectomy: The FAIRY randomized clinical trial. JAMA 2017;317(20):2097–2104. DOI: 10.1001/jama.2017.5703.
  16. Jose A, Mahey R, Sharma JB, et al. Comparison of ferric carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy-randomised controlled trial. BMC Pregnancy Childbirth 2019;19(1):54. DOI: 10.1186/s12884-019-2200-3.
  17. Lyseng–Williamson KA, Keating GM. Ferric carboxymaltose. Drugs 2009;69(6):739–756. DOI: 10.2165/00003495-200969060-00007.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.